Nuvation Bio Inc (NUVB) Q3 2026 Earnings Call Highlights: IBTROZI Revenue Climbs 18%

Nuvation Bio (NUVB) reported Q3 earnings, highlighting IBTROZI revenue growth and advancements in safusidenib studies. Management expects continued growth and potential milestone payments. Q3 revenue was $17.5M, with $159.9M total revenue for the first nine months. The company has $663.4M in cash and believes it has sufficient capital to reach profitability.

Nuvation Bio Inc. (NUVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed

Nuvation Bio (NYSE: NUVB) reported Q3 2026 revenue of $45.0M, with $27.5M from IBTROZI®. IBTROZI, a ROS1 TKI, is the market leader in new patient starts and total active patients. FDA approved a label update for IBTROZI, reflecting a 49.7-month median duration of response. The FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma. The company had $663.4M in cash as of September 30, 2026.

Nuvation Bio Inc. reports Q3 earnings, with analysts expecting a loss of 12 cents per share on $35.1M revenue. IBTROZI, its lung cancer drug, is key, with revenue and patient mix under scrutiny. The stock has fallen 25% in 3 months, trading near its 52-week low. Analysts have a mean price target of $13, implying 177% upside from the current $4.69 price.

Nuvation Bio (NYSE: NUVB) will present updated Phase 2 results and ongoing trial overviews for safusidenib, its investigational IDH1 inhibitor, at the 2026 SNO Annual Meeting. The presentation includes additional data from the Phase 2 J201 study, previously announced in July 2026. Safusidenib is being studied for IDH1-mutant glioma, a type of brain cancer with significant unmet medical needs.

Nuvation Bio (NYSE:NUVB) expanded its Phase 3 SIGMA trial of safusidenib to six European countries, adding to existing sites in the U.S., Australia, China, Canada, and Japan. The study evaluates safusidenib as maintenance therapy for IDH1-mutant astrocytoma, with a primary endpoint of progression-free survival. The trial plans to enroll 300 patients, with an exploratory cohort of 40. The FDA granted Fast Track Designation to safusidenib in August 2026.